TY - JOUR
T1 - A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation
AU - Morichika, Daisuke
AU - Miyahara, Nobuaki
AU - Fujii, Utako
AU - Taniguchi, Akihiko
AU - Oda, Naohiro
AU - Senoo, Satoru
AU - Kataoka, Mikio
AU - Tanimoto, Mitsune
AU - Kakuta, Hiroki
AU - Kiura, Katsuyuki
AU - Maeda, Yoshinobu
AU - Kanehiro, Arihiko
N1 - Funding Information:
This study is supported in part by a grant from the Ministry of Education, Science, and Culture of Japan, 2646118906 (A.K.). This study is supported in part by the Translational Research Network Program from the Japan Agency for Medical Research and Development, AMED (H.K.).
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/1/3
Y1 - 2019/1/3
N2 - Background: Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-activated receptors. The NR family may also play important roles in the development of emphysema. However, the role of RXRs in the pathogenesis of emphysema is not well defined. Methods: We developed a novel RXR partial agonist (NEt-4IB) and investigated its effect and mechanism compared to a full agonist (bexarotene) in a murine model of emphysema. For emphysema induction, BALB/c mice received intraperitoneal cigarette smoke extract (CSE) or intratracheal porcine pancreas elastase (PPE). Treatment with RXR agonists was initiated before or after emphysema induction. Results: Treatment with NEt-4IB significantly suppressed the increase in static lung compliance and emphysematous changes in CSE-induced emphysema and PPE-induced established and progressive emphysema. NEt-4IB significantly suppressed PPE-induced neutrophilic airway inflammation and the levels of keratinocyte chemoattractant (KC), C-X-C motif ligand5 (CXCL5), interferon (IFN)-γ and IL-17. NEt-4IB also improved the matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and the reduced anti-oxidant activity in bronchoalveolar lavage (BAL) fluid. NEt-4IB suppressed PPE-induced vascular endothelial growth factor (VEGF) expression in the airway. Treatment with NEt-4IB and bexarotene significantly suppressed the increase in static lung compliance and emphysematous changes. However, adverse effects of RXR agonists, including hypertriglyceridemia and hepatomegaly, were observed in bexarotene-treated mice but not in NEt-4IB-treated mice. Conclusion: These data suggest that RXRs play crucial roles in emphysema and airway inflammation, and novel partial RXR agonists could be potential therapeutic strategies for the treatment of PPE- and CSE-induced emphysema.
AB - Background: Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-activated receptors. The NR family may also play important roles in the development of emphysema. However, the role of RXRs in the pathogenesis of emphysema is not well defined. Methods: We developed a novel RXR partial agonist (NEt-4IB) and investigated its effect and mechanism compared to a full agonist (bexarotene) in a murine model of emphysema. For emphysema induction, BALB/c mice received intraperitoneal cigarette smoke extract (CSE) or intratracheal porcine pancreas elastase (PPE). Treatment with RXR agonists was initiated before or after emphysema induction. Results: Treatment with NEt-4IB significantly suppressed the increase in static lung compliance and emphysematous changes in CSE-induced emphysema and PPE-induced established and progressive emphysema. NEt-4IB significantly suppressed PPE-induced neutrophilic airway inflammation and the levels of keratinocyte chemoattractant (KC), C-X-C motif ligand5 (CXCL5), interferon (IFN)-γ and IL-17. NEt-4IB also improved the matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) imbalance and the reduced anti-oxidant activity in bronchoalveolar lavage (BAL) fluid. NEt-4IB suppressed PPE-induced vascular endothelial growth factor (VEGF) expression in the airway. Treatment with NEt-4IB and bexarotene significantly suppressed the increase in static lung compliance and emphysematous changes. However, adverse effects of RXR agonists, including hypertriglyceridemia and hepatomegaly, were observed in bexarotene-treated mice but not in NEt-4IB-treated mice. Conclusion: These data suggest that RXRs play crucial roles in emphysema and airway inflammation, and novel partial RXR agonists could be potential therapeutic strategies for the treatment of PPE- and CSE-induced emphysema.
KW - Anti-oxidant activity
KW - Emphysema
KW - Matrix metalloproteinase-9
KW - Neutrophilic airway inflammation
KW - Retinoid X receptor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85059502773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059502773&partnerID=8YFLogxK
U2 - 10.1186/s12931-018-0963-0
DO - 10.1186/s12931-018-0963-0
M3 - Article
C2 - 30606200
AN - SCOPUS:85059502773
SN - 1465-9921
VL - 20
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 2
ER -